Vijay Iyengar compensation by year
INCYTE Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $552,278 |
| Bonus | $0 |
| Stock awards | $1,418,393 |
| Option awards | $940,557 |
| Non-equity incentive | $353,299 |
| Pension and deferred compensation | $0 |
| All other | $40,323 |
| Total | $3,304,850 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INCYTE CORP DEF 14A filed April 16, 2021, accession 0001047469-21-000962, and prior-year filings. Open the filing on EDGAR.
How this page was built: the INCYTE CORP filed document, accession 0001047469-21-000962. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 6,661 | $579,374 | — |
| PSU | 5,429 | $472,214 | — |
| RSU | 5,161 | $448,904 | — |
| RSU | 5,071 | $441,076 | — |
| RSU | 2,695 | $234,411 | — |
| RSU | 1,232 | $107,159 | — |
| RSU | 880 | $76,542 | — |
| Option | 1,769 | — | $94.63 |
| Option | 9,014 | — | $72.27 |
| Option | 10,610 | — | $85.01 |
| Option | 10,610 | — | $80.50 |
| Option | 18,865 | — | $113.64 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INCYTE CORP's FY2020 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.
Insider transactions since the last proxy
31 Form 4 lines since the FY2020 proxy (filed April 16, 2021)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-07-16 | Sale | 10b5-1 | 983 | $68.36 | 40,540 |
| 2025-07-15 | Grant or award derivative | 10b5-1 | 14,472 | $0.00 | 14,472 |
| 2025-07-15 | Grant or award derivative | 10b5-1 | 16,077 | $0.00 | 16,077 |
| 2025-07-15 | Tax withholding | 10b5-1 | 836 | $68.25 | 35,093 |
| 2025-07-15 | Grant or award | 10b5-1 | 6,430 | $0.00 | 41,523 |
| 2025-07-15 | Sale | 10b5-1 | 1,177 | $69.86 | 35,929 |
| 2025-07-14 | Tax withholding | 10b5-1 | 595 | $69.98 | 37,106 |
| 2025-07-03 | Sale | 10b5-1 | 2,682 | $68.16 | 43,636 |
The 8 most recent of 31 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
INCYTE’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Hervé Hoppenot | President and Chief Executive Officer | $16,378,192 |
| Christiana Stamoulis | Executive Vice President and Chief Financial Officer | $4,154,250 |
| Barry Flannelly | Executive Vice President and General Manager—NA | $4,116,884 |
| Steven Stein | Executive Vice President and Chief Medical Officer | $3,326,750 |
| Vijay Iyengar · this page | Executive Vice President, Global Strategy and Corporate Development | $3,304,850 |
| Maria Pasquale | Executive Vice President, General Counsel and Corporate Secretary | $3,270,971 |
The full INCYTE compensation record
free company briefThis page is one person within INCYTE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the INCYTE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INCYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.